gemcitabine has been researched along with orlistat in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Avan, A; Bononi, G; Brai, A; Caligiuri, I; Chicca, A; Di Stefano, M; Dreassi, E; Gertsch, J; Giovannetti, E; Granchi, C; Macchia, M; Masetto, F; Meier, P; Minutolo, F; Ortore, G; Poli, G; Rizzolio, F; Tuccinardi, T; Vagaggini, C; Valoti, M | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Cheng, H; Ding, J; Ma, F; Sun, Y; Wang, S; Yu, X; Zhou, D | 1 |
1 review(s) available for gemcitabine and orlistat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for gemcitabine and orlistat
| Article | Year |
|---|---|
Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives.
Topics: Cell Proliferation; Enzyme Inhibitors; Humans; Monoacylglycerol Lipases; Monoglycerides; Pancreatic Neoplasms | 2022 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
FASN promotes gallbladder cancer progression and reduces cancer cell sensitivity to gemcitabine through PI3K/AKT signaling.
Topics: Animals; Fatty Acid Synthase, Type I; Fatty Acid Synthases; Gallbladder Neoplasms; Gemcitabine; Humans; Mice; Mice, Nude; Orlistat; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2023 |